PCORI Just Opened $120 Million for Health Research — and It May Be the Most Stable Funding in Federal Science Right Now

While NIH program officers brace for Schedule Policy/Career reclassification and researchers watch their fundable R01 scores languish in payment limbo, a different kind of health research funder just quietly opened five simultaneous funding tracks worth up to $120 million in direct costs — with a deadline less than three weeks away.

The Patient-Centered Outcomes Research Institute is not new. Congress created it in 2010 as part of the Affordable Care Act, and it has spent over $4 billion on comparative clinical effectiveness research since then. But PCORI's Cycle 2 2026 announcement, which opened April 1 with letters of intent due April 28, arrives at a moment that makes it more strategically important than at any point in its history.

Here is why: PCORI operates outside the federal appropriations process. It is funded by a dedicated trust fund sustained by fees on private health insurance plans and self-insured employers — not by the annual congressional budget cycle that has turned NIH funding into a political football. When the administration proposes cutting NIH by 57 percent, PCORI's budget does not flinch. When DOGE terminates 1,752 NSF grants, PCORI's review panels keep meeting. When federal grant makers face at-will reclassification, PCORI's staff operate under a different employment structure entirely.

That structural independence is worth understanding if you write health research grants for a living.

What PCORI Is Actually Funding

The Broad Pragmatic Studies track is the flagship — up to $120 million in direct costs, with individual awards ranging from $5 million to $12 million over five years. This is not seed funding. These are full-scale, multi-site pragmatic trials and observational studies designed to change clinical practice.

PCORI has identified four priority health areas for this cycle: diabetes prevention and treatment, obesity management interventions, urogynecological and pelvic pain management, and pain management for sickle cell disease. But the announcement explicitly welcomes applications on any health topic, and the scoring rubric does not penalize researchers who fall outside the priority areas — it rewards scientific rigor and patient-centeredness regardless of disease focus.

The scale of the awards matters. At $12 million in direct costs, a PCORI Broad Pragmatic Study is comparable to a large NIH U01 cooperative agreement or an R01 with multiple supplements. For researchers who have been building multi-site trial networks through NIH mechanisms, PCORI offers an alternative track that is funded, stable, and not subject to the payline uncertainty that has made NIH forward-funding so unpredictable.

Beyond the flagship, four additional tracks opened simultaneously:

Phased Large Awards for Comparative Effectiveness Research (PLACER): A two-phase mechanism — feasibility study first, then scale-up — designed for projects that need to demonstrate proof of concept before committing to a full trial. This is unusually flexible for a federal-adjacent funder and fills a gap that NIH's R34/R01 pathway handles clumsily.

Addressing Sensory Health Needs Across the Lifespan: A targeted opportunity for vision, hearing, and sensory processing research, with three special areas of emphasis. The specificity here is notable — PCORI has identified a gap in the evidence base and is directing funding toward it, rather than waiting for investigators to bring it up.

Advancing the Science of Engagement in Research: Funds methodological work on how to involve patients and stakeholders in research design, execution, and dissemination. If you have been struggling to fund your community-engaged research methods work through traditional NIH mechanisms, this is your track.

Improving Methods for Conducting Patient-Centered CER: Up to $750,000 per project for methodological innovation — specifically flagging AI/ML applications, real-world data use, and patient-centered measurement as priority areas. The AI/ML emphasis is new for PCORI and reflects the broader shift across all funders toward computational approaches in health research.

How PCORI Review Differs from NIH

If you are an NIH-trained investigator, PCORI's review process will feel familiar in some ways and foreign in others. Understanding the differences is essential to writing a competitive application.

Patient engagement is not optional — it is scored. PCORI's Foundational Expectations for Partnerships in Research require meaningful patient and stakeholder involvement throughout the research lifecycle. This is not a letter of support from a patient advisory board. Reviewers evaluate whether patients and stakeholders have genuinely shaped the research question, study design, outcome selection, and dissemination plan. Proposals that bolt on engagement as an afterthought score poorly.

Comparative effectiveness is the lens. Every PCORI-funded study must compare two or more clinical or healthcare delivery interventions. Mechanistic research, basic science, and single-arm studies are out of scope. If your research question is "does intervention X work?" the answer is to apply to NIH. If your question is "for patients with condition Y, is intervention X or intervention Z more effective, and for whom?" that is a PCORI question.

Pragmatic design is strongly preferred. The Broad Pragmatic Studies track explicitly encourages randomized controlled trials conducted in real-world clinical settings — PCORnet sites, health system networks, community health centers. PCORI wants research that can be implemented immediately after the trial concludes, not efficacy studies that require a decade of translational work.

The LOI matters more than you think. PCORI's application process is invitation-only after the letter of intent stage. Unlike NIH, where you submit an R01 and it goes to study section regardless, a weak PCORI LOI means you never get the chance to submit a full application. The April 28 LOI deadline is the real gate — treat it with the same seriousness you would bring to a full NIH submission.

The Strategic Case for PCORI in 2026

For health researchers navigating the current federal funding landscape, PCORI solves three problems simultaneously.

Funding stability. PCORI's trust fund is authorized through 2029, and reauthorization enjoys bipartisan support because the funding mechanism — fees on health insurers — does not compete with discretionary spending. When Congress fights over NIH appropriations, PCORI is not on the table. When the administration proposes agency restructuring, PCORI's independent charter provides insulation. This does not make PCORI immune to political pressure, but it makes it meaningfully more predictable than any agency funded through the annual appropriations process.

Review independence. The controversy over Schedule Policy/Career — the reclassification that could make federal grant reviewers at-will employees subject to political pressure — does not apply to PCORI. Its methodology committees and merit reviewers operate outside the federal civil service structure. For researchers concerned about whether their NIH study section scores reflect scientific merit or political alignment, PCORI offers a review process that is structurally insulated from that pressure.

Complementary, not competitive. PCORI does not fund the same research as NIH. It funds the downstream question — once efficacy is established, which approach works better in practice, for which patients, under what conditions? This means a well-designed research program can have an NIH-funded mechanistic arm and a PCORI-funded pragmatic comparison arm running simultaneously. The two funding streams are additive, not substitutive.

Who Should Apply — and Who Should Not

PCORI is not the right funder for everyone. Basic scientists, discovery researchers, and investigators focused on disease mechanisms will not find a fit here. PCORI does not fund preclinical work, Phase I/II trials, or single-arm studies. The comparative effectiveness requirement is real, and trying to shoehorn a basic science question into a CER framework will not fool reviewers.

The strongest candidates are clinical and health services researchers with access to large patient populations, established multi-site networks, and genuine partnerships with patient communities. If you run a health system that touches thousands of patients with a condition where two standard-of-care treatments exist and nobody knows which one is better for which subgroups — that is the sweet spot.

Early- and mid-career investigators should note that the Broad Pragmatic Studies track includes structured mentorship funding. PCORI will fund mentorship activities within awards, providing protected time for junior investigators to develop independent research programs. This is a meaningful differentiator from NIH K-to-R01 transitions, which require separate applications for training and research funding.

The April 28 Deadline

Letters of intent are due April 28 at 5 PM Eastern. Invited full applications follow September 1, with awards announced in April 2027 and the earliest project start in August 2027.

Three weeks is tight for a letter of intent, but PCORI LOIs are deliberately concise — they are designed to assess the research question, the team, and the feasibility of the study, not to require a fully developed protocol. If you have been thinking about a pragmatic trial that did not fit cleanly into an NIH mechanism, this is the deadline that should be on your calendar.

The broader point is this: the researchers who thrive in the current funding environment will be the ones who treat their grant portfolio the way a financial advisor treats an investment portfolio — diversified across mechanisms, agencies, and funding structures. PCORI is not a replacement for NIH. It is a hedge against the instability that has made NIH funding unreliable, and right now it is offering $120 million to prove that point.

If you are building a diversified funding strategy across NIH, PCORI, foundation, and agency grants, Granted can help you identify which opportunities match your research profile and track deadlines across all of them in one place.